Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Presage Biosciences Adds Board Member

Executive Summary

The oncology company Presage Biosciences has appointed David Johnson to its board of directors. With 25 years’ experience Johnson joins Presage from the oncology focused company, Acerta Pharma, where he was CEO.  He has held roles with increasing responsibilities within clinical development, medical affairs, pipeline development, and commercial at companies including Calistoga (acquired by Gilead), Gloucester (acquired by Celgene), Favrille, Millennium, Immunex (acquired by Amgen), and Hoffman La Roche.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register